Azaquinolinone derivatives and uses thereof

• US 8,343,996 B2
• Filed: 11/13/2009
• Issued: 01/01/2013
• Est. Priority Date: 11/13/2008
• Status: Expired due to Fees

• Current Assignee: Astrazeneca AB (Astrazeneca PLC)
• Original Assignee: Astrazeneca AB (Astrazeneca PLC)
• Inventors: Duggan, Mark E.
• Primary Examiner(s): Rahmani, Niloofar
• Application Number:
  US12/618,336
• Publication Number:
  US 20100130540A1
• Time in Patent Office: 1,145 Days
• Field of Search: 546/122, 514/300
• US Class Current: 514/300
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 471/04 : Ortho-condensed systems
• CPC Class Codes: C07D 519/00 : Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

The present invention provides compounds and methods for treating or preventing the development of a disease, disorder, or condition in a subject or patient.

Claims

1. A compound of formula I:

2. The compound of claim 1 of formula I-a:

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein is a double bond.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R¹ is phenyl, and wherein R¹ is optionally substituted with 0-5 —

R^w.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R³ is a 5 membered monocyclic heteroaryl ring having 1-3 hetero atoms independently selected from nitrogen, oxygen, and sulfur, and optionally substituted with 1-2 R^x groups.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R⁴ is phenyl substituted with 0-3 R^y groups.

7. The compound of claim 1 of formula I-q:

8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein at least one Rw group is independently selected from the group consisting of R, halogen, —

OR, —

N(R′

)₂, and —

C(R)₃.

9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R² is selected from the group consisting of —

OR, halogen, and —

N(R′

)₂.

10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R⁵ is an acyclic C_1-12 aliphatic moiety.

11. The compound of claim 1 having any one of the following structures:

12. A pharmaceutical composition comprising a compound claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

13. The compound